Stock Market Reviews

Read and share opinions on PHAT (Phathom Pharmaceuticals, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock m

Latest News

• Could Clinical Progress With VOQUEZNA Reshape Phathom Pharmaceuticals’ Long-Term Strategy (PHAT)?
  Nov 13, 2025
• Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
  Nov 4, 2025
• Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
  Nov 3, 2025
• Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Just Reported And Analysts Have Been Lifting Their Price Targets
  Nov 2, 2025
• Phathom Pharmaceuticals (PHAT): Forecasts Call for 75% Annual Earnings Growth as Losses Deepen
  Oct 31, 2025
• Phathom Pharmaceuticals Inc (PHAT) Q3 2025 Earnings Call Highlights: Revenue Surge and ...
  Oct 30, 2025
• Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates
  Oct 30, 2025
• Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
  Oct 30, 2025
• With 51% ownership of the shares, Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) is heavily dominated by institutional owners
  Oct 28, 2025
• Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
  Oct 23, 2025
• Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer
  Oct 6, 2025
• Phathom Pharmaceuticals (NASDAQ:PHAT) adds US$64m to market cap in the past 7 days, though investors from five years ago are still down 67%
  Sep 24, 2025
• Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's Why
  Sep 18, 2025
• Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High?
  Sep 8, 2025
• Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet
  Aug 22, 2025
• Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing
  Aug 20, 2025
• Phathom Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS In Line
  Aug 9, 2025
• Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
  Aug 7, 2025
• Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
  Aug 7, 2025